Novartis takes $1.9bn hit from Avidity takeover in Q3
Novartis's third-quarter results included a $1.9bn impairment relating to its $12bn takeover of Avidity, though CEO insists it remains a good deal.
Anthropic sets out its biopharma ambitions in IPO doc
Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."
ESMO26: Ris-rez offers hope of osteosarcoma breakthrough
There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.
Judge backs Lilly in Novo lawsuit over weight-loss drug ads
A US judge has blocked Novo's request for an injunction on Eli Lilly's advertising for weight-loss and diabetes drugs Mounjaro and Zepbound.
Bayer gets first approval for stroke drug asundexian
Bayer's oral Factor XIa inhibitor asundexian has been cleared in its first market, China, for secindary stroke prevention.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
31st Edition Strategic Project & Portfolio Management for Ph...
The Marcus Evans 31st Edition Strategic Project & Portfolio Management for Pharma conference, for European pharmaceutical PMO and portfolio leaders.
Women in AI - an evening of practical AI learning
Women in AI returns November 10 in London, UK. Join women from across healthcare for an evening of practical AI learning.
UAE investment drives Middle East biopharma transformation a...
Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in the Middle East over the ne
Europe's Largest Gathering for ADC Innovation
Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community
PharmaMarketing Summit 2027 to Convene America's Top Pharmac...
Elite industry leaders will gather to address AI-driven engagement, launch excellence, and the future of market access at an exclusive, invitation-only event